<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01163838</url>
  </required_header>
  <id_info>
    <org_study_id>B1481002</org_study_id>
    <nct_id>NCT01163838</nct_id>
  </id_info>
  <brief_title>Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia</brief_title>
  <official_title>A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Multiple Intravenous Doses Of RN316 In Healthy Adult Subjects With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of repeated
      doses of RN316 in eligible healthy volunteers. RN316 is an investigational drug that is
      currently being studied as a cholesterol lowering therapy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was redesigned based on FDA feedback.
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">March 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting or intolerable treatment related adverse events (AEs).</measure>
    <time_frame>Every Scheduled Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence, severity and causal relationship of treatment emergent AEs (TEAEs).</measure>
    <time_frame>Every Scheduled Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of abnormal and clinically relevant safety laboratories.</measure>
    <time_frame>Screening and Days 29, 57, 85, 113, 135, 141, 169 and 197</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Abnormal and clinically relevant changes in vital signs, BP, and ECG parameters.</measure>
    <time_frame>Every Scheduled Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of anti-drug-antibodies.</measure>
    <time_frame>Baseline and Day 15 and monthly thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter estimates including but not be limited to: AUC, Tmax, Cmax terminal elimination half life (t1/2), Clearance (CL), volume of distribution at steady state (Vss), and accumulation ratio (R) of RN316.</measure>
    <time_frame>Day 1 and every scheduled visit thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and percentage change in LDL C from baseline.</measure>
    <time_frame>Every scheduled visit except Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve a target LDL C of &lt;100 mg/mL.</measure>
    <time_frame>Every scheduled visit except Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve a target LDL C of &lt;70 mg/dL.</measure>
    <time_frame>Every scheduled visit except Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving 50% decrease in LDL C from baseline.</measure>
    <time_frame>Every scheduled visit except Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RN316: 1 mg/kg every 2 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RN316: 2 mg/kg every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RN316: 4 mg/kg every 4 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RN316: 4 mg/kg every 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RN316: 8 mg/kg every 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RN316: 12 mg/kg every 8 weeks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>1 mg/kg every 2 weeks</intervention_name>
    <description>Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.</description>
    <arm_group_label>RN316: 1 mg/kg every 2 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2 mg/kg every 4 weeks</intervention_name>
    <description>Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.</description>
    <arm_group_label>RN316: 2 mg/kg every 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4 mg/kg every 4 weeks</intervention_name>
    <description>Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.</description>
    <arm_group_label>RN316: 4 mg/kg every 4 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>4 mg/kg every 8 weeks</intervention_name>
    <description>Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.</description>
    <arm_group_label>RN316: 4 mg/kg every 8 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>8 mg/kg every 8 weeks</intervention_name>
    <description>Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.</description>
    <arm_group_label>RN316: 8 mg/kg every 8 weeks</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>12 mg/kg every 8 weeks</intervention_name>
    <description>Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.</description>
    <arm_group_label>RN316: 12 mg/kg every 8 weeks</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  LDL-C must be greater or equal to 130 mg/dl

          -  BMI must be between 18.5 and 40 kg/m2

        Exclusion Criteria:

          -  History of cardiovascular or cerebrovascular event during the past year.

          -  Poorly controlled type 1 or type 2 diabetes mellitus

          -  Subjects who have taken lipid lowering therapies within the last 3 months of
             screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1481002&amp;StudyName=Multiple-Dose%20Safety%20Study%20Of%20RN316%20For%20TheTreatment%20Of%20Hypercholesterolemia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>April 21, 2015</last_update_submitted>
  <last_update_submitted_qc>April 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypercholesterolemia</keyword>
  <keyword>Dyslipidemia</keyword>
  <keyword>LDL</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>High Cholesterol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

